Healthcare Stocks Outlook (Dec. 25, 2025): Wegovy Pill Breakthrough, FDA Approvals, and a New Wave of M&A Heading Into 2026
The FDA approved Novo Nordisk’s oral Wegovy pill for chronic weight management, marking the first U.S. approval of an oral GLP‑1 for obesity. The decision sent biotech shares higher and intensified competition in the obesity drug market. U.S. markets were closed for Christmas. Novo Nordisk plans a U.S. launch in early January 2026.